Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
Borosil Renew.

Borosil Renewables will hold a meeting of the Board of Directors of the Company on 27 May 2024.

Cipla

Cipla USA Inc., wholly owned subsidiary of Cipla USA has received the final approval for its Abbreviated New Drug Application (ANDA) for Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL from USFDA.

Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline® Depot (lanreotide) Injection and is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs).

The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.

According to IQVIA (IMS Health), Somatuline® Depot (Lanreotide) had US sales of approximately $898M for the 12-month period ending March 2024.

Kiran Syntex

Kiran Syntex will hold a meeting of the Board of Directors of the Company on 29 May 2024.

Ace Engitech

Prem Somani Financial Services will hold a meeting of the Board of Directors of the Company on 28 May 2024

Terai Tea Co

Terai Tea Co will hold a meeting of the Board of Directors of the Company on 29 May 2024

Sampre Nutrition

Sampre Nutritions will hold a meeting of the Board of Directors of the Company on 30 May 2024.

Capital India

Capital India Finance announced that the Board of Directors of the Company at its meeting held on 22 May 2024, inter alia, have recommended the final dividend of Rs 0.1 per equity Share (i.e. 1%) , subject to the approval of the shareholders.

Remsons Ind

Remsons Industries will hold a meeting of the Board of Directors of the Company on 28 May 2024.

Mefcom Capital

Mefcom Capital Markets will hold a meeting of the Board of Directors of the Company on 28 May 2024

Visagar Finan.

Visagar Financial Services will hold a meeting of the Board of Directors of the Company on 30 May 2024

<< < 1 2 3 4   > >>